Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 148,600 shares, effective November 3, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly for 36 months), have a 10-year term, and an exercise price of $8.42 per share, equal to the last reported sale price on Nasdaq on November 3, 2025.
Olema Oncology (Nasdaq: OLMA) will participate in three investor conferences in November 2025: a Guggenheim fireside chat on Nov 10, 2025 at 10:30 a.m. ET in Boston; a UBS presentation on Nov 12, 2025 at 8:00 a.m. ET in Palm Beach; and a Jefferies London fireside chat on Nov 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET in London.
Live webcasts and recordings will be available, as permitted by event hosts, in the Events and Presentations section of Olema’s investor relations site at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) will present a trial-in-progress poster for the Phase 3 OPERA-02 study at the 2025 San Antonio Breast Cancer Symposium (SABCS 2025) on December 12, 2025.
The randomized, double-blind, active-controlled trial compares palazestrant plus ribociclib versus letrozole plus ribociclib as first-line therapy for ER+, HER2- advanced or metastatic breast cancer. Poster: Abstract 264, Presentation PS5-12-18, 12:30pm–2:00pm CT. A poster copy will be posted on Olema's publications page per SABCS embargo policy.
Olema Oncology (Nasdaq: OLMA) reported updated Phase 1b/2 data for palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer presented at ESMO 2025 on October 20, 2025.
Key clinical readouts: in the 120 mg palazestrant cohort (n=56, median follow-up >19 months) median PFS was 15.5 months overall; among patients with prior CDK4/6 inhibitor therapy median PFS was 12.2 months (9.2 months for ESR1 wild-type; 13.8 months for ESR1 mutant). Across 72 patients, the combination showed favorable tolerability, no new safety signals, and no drug-drug interactions. Data support the ongoing Phase 3 OPERA-02 trial in the frontline setting.
Olema Oncology (Nasdaq: OLMA) granted stock options to three new employees for an aggregate of 77,000 shares, effective October 1, 2025, approved under the company's 2022 Inducement Plan as required by Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then 36 equal monthly installments), have a 10-year term, and an exercise price of $11.04 per share (equal to the last reported sale price on Nasdaq on October 1, 2025). Olema disclosed the awards to comply with Nasdaq rules governing inducement grants.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees under its 2022 Inducement Plan. The grants total 124,000 shares with an exercise price of $6.47 per share.
The stock options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining portion vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) has announced a new clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate the combination of palazestrant and atirmociclib in patients with ER+/HER2- metastatic breast cancer.
The Phase 1b/2 study will assess the safety and combinability of Olema's palazestrant with Pfizer's investigational CDK4 inhibitor atirmociclib in approximately 35 patients, with trial initiation expected in H2 2025. Results will inform a potential pivotal Phase 3 trial in frontline metastatic breast cancer.
Under the agreement, Pfizer will supply atirmociclib while Olema leads the study. Both companies will jointly own clinical data and inventions, with Olema retaining full global commercial rights to palazestrant.
Olema Oncology (NASDAQ:OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in five major investor conferences in September 2025.
The company will present at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), and H.C. Wainwright Global Investment Conference (Sept 9). All conferences will take place in Boston and New York, featuring a mix of presentations and fireside chats.
Investors can access live webcasts and recordings through Olema's investor relations website at ir.olema.com.
Olema Oncology (Nasdaq: OLMA) has reported its Q2 2025 financial results and provided key operational updates. The company has selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 trial and the OPERA-02 Phase 3 trial in combination with ribociclib for breast cancer treatment.
Key financial metrics include $361.9 million in cash and equivalents, and a net loss of $43.8 million for Q2 2025, compared to $30.4 million in Q2 2024. R&D expenses increased to $43.9 million, primarily due to a $10 million milestone payment to Aurigene and increased clinical development activities.
The company expects to present mature data from the Phase 1b/2 study at ESMO 2025, initiate OPERA-02 in Q3 2025, and report OPERA-01 top-line data in H2 2026.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 130,000 shares of common stock with an exercise price of $5.33 per share.
The stock options, approved under the Company's 2022 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
